ALEC Nasdaq Earnings call
Alector, Inc. (ALEC) · Q2 2025 results
Share price: $2.63 · 2026-11-11
Results Q2 2025 vs Q4 2024 · previous quarter · published 9 Aug 2025 and 27 Feb 2025
Management sounded restrained, in its script and in answers to analysts.
Only a basic analysis is available for this company at the moment.
1 · Numbers
—
No financial figures for this pair
Outlook given
2 · How management spoke
Restrained
Less upbeat than 80% of company calls
Answers to analysts: cautious, in line with the script.
Similar to last call.
3 · What stood out
New
Ryan Darby, Associate Professor of Neurology and Director of the Frontotemporal Dementia It is my pleasure to introduce Dr.
Valuation
Reverse DCF. Free cash flow from the last full fiscal year, grown for 10 years, discounted back, plus a terminal value. “Implied growth” is the rate the current price assumes.
Valuation unavailable: free cash flow and profit were negative in the last full year and on average over the last three, so there is nothing to discount.
Current price
$2.63
close of 2026-11-11
Revenue growth, 3 years
−46.0% a year
compound annual rate (CAGR)
Free cash flow 2023
−$0.2B
Free cash flow 2024
−$0.2B
Free cash flow 2025
−$0.2B
Read between the lines
-
Guidance
ALEC expects top-line data by mid-fourth quarter from Phase III INFRONT-3 trial of latozinemab, the first rigorous test of a progranulin-elevating approach for frontotemporal dementia due to the GRN gene.
Source quote
“This trial represents the first rigorous test of progranulin elevating approach to treating frontotemporal dementia due to the GRN gene... By mid-fourth quarter, we expect top line data from our pivotal Phase III INFRONT-3 trial of latozinemab, our most advanced clinical program. We designed latozinemab based on clear biological and human genetic...”
Tone
How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: Q2 2025. Ring: Q4 2024.
Script and answers carried a similar tone, so the script's message held up under questioning.
Sentences that drove the tone
“These programs are grounded in the same principles that define our clinical portfolio, a strong genetic and biological rationale and high transformational potential and a focus on serious neurodegenerative diseases...”
“With increased understanding of the genetic underpinnings like GRN mutation and the development of robust biomarkers, we're now in a position to truly develop transformative therapies.”
“As you've heard today, we are advancing our late-stage clinical programs, which have a strong scientific rationale, robust trial designs and meaningful regulatory engagement.”
Topics
Most discussed now
- It is striking how many people living with FTD still have no approved treatment options today, underscoring the need for...
- With this context in mind, I want to provide a deeper overview of the science behind Alector's...
- This neurodegeneration leads to a broad range of symptoms, and Alector categorizes FTD into different clinical subtypes based on those...
- FTD is not a single disease, but instead a group of disorders caused by progressive neuronal cell loss in the...
- Treatment with latozinemab normalized plasma and CSF progranulin levels, resulting in a two to threefold increase that was rapid and...
Faded since Q4 2024
- Dropped Because it conceptually could be utilized for antibody therapeutics, enzyme replacement therapy, nucleic acid therapy, it could improve...
- Dropped To achieve Alector continues to build an integrated biotechnology organization that combines deep expertise in genetics, immunology and…
- Dropped There are pockets of patients in different countries in Italy and Portugal et cetera and other where there are founder...
- Fading These programs are more advanced and Alector's goal is to get to an IND submission and to be in the...
Latest announcements
Official filings, newest first.
- Material agreement; Results of operations; Regulation FD disclosure; Other events · SEC 8-K
- Results of operations · SEC 8-K
- Agreement terminated · SEC 8-K
- Shareholder vote results · SEC 8-K
- Material agreement · SEC 8-K
- Results of operations · SEC 8-K
- Results of operations · SEC 8-K
- Director or officer change · SEC 8-K